WuXi Biologics (Cayman) Inc.

SEHK:2269 Voorraadrapport

Marktkapitalisatie: HK$59.1b

WuXi Biologics (Cayman) Beheer

Beheer criteriumcontroles 2/4

De CEO WuXi Biologics (Cayman) is Chris Chen, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 96.91M, bestaande uit 4.1% salaris en 95.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde HK$ 208.62M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 7.2 jaar.

Belangrijke informatie

Chris Chen

Algemeen directeur

CN¥96.9m

Totale compensatie

Percentage CEO-salaris4.1%
Dienstverband CEO8.8yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn2.6yrs
Gemiddelde ambtstermijn bestuur7.2yrs

Recente managementupdates

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Recent updates

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Sep 12
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11
Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04
Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08
Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Nov 26
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Nov 10
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

Sep 26
What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26
These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10
WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13
At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13
Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30
An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09
Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20
Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08
With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15
Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Analyse CEO-vergoeding

Hoe is Chris Chen's beloning veranderd ten opzichte van WuXi Biologics (Cayman)'s winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

CN¥3b

Mar 31 2024n/an/a

CN¥3b

Dec 31 2023CN¥97mCN¥4m

CN¥3b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥79mCN¥3m

CN¥4b

Sep 30 2022n/an/a

CN¥4b

Jun 30 2022n/an/a

CN¥4b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥51mCN¥3m

CN¥3b

Sep 30 2021n/an/a

CN¥3b

Jun 30 2021n/an/a

CN¥3b

Mar 31 2021n/an/a

CN¥2b

Dec 31 2020CN¥31mCN¥3m

CN¥2b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥1b

Dec 31 2019CN¥25mCN¥3m

CN¥1b

Sep 30 2019n/an/a

CN¥922m

Jun 30 2019n/an/a

CN¥831m

Mar 31 2019n/an/a

CN¥731m

Dec 31 2018CN¥20mCN¥2m

CN¥631m

Sep 30 2018n/an/a

CN¥520m

Jun 30 2018n/an/a

CN¥410m

Mar 31 2018n/an/a

CN¥331m

Dec 31 2017CN¥24mCN¥2m

CN¥253m

Compensatie versus markt: De totale vergoeding ($USD 13.37M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 887.42K ).

Compensatie versus inkomsten: De beloning van Chris is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.


CEO

Chris Chen (51 yo)

8.8yrs

Tenure

CN¥96,911,000

Compensatie

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Ge Li
Founder & Chairman10.8yrsgeen gegevensgeen gegevens
Zhisheng Chen
CEO & Executive Director8.8yrsCN¥96.91m0.35%
HK$ 208.6m
Weichang Zhou
Honorary President of Global Biologics Development9.6yrsCN¥32.89m0.013%
HK$ 8.0m
Ming Tu
CFO & Executive VP3yrsgeen gegevensgeen gegevens
Lihua Yu
COO & Senior VPless than a yeargeen gegevensgeen gegevens
Sherry Gu
Chief Technology Officer and Executive VP of Global Biologics Development Departmentless than a yeargeen gegevensgeen gegevens
Jijie Gu
Chief Scientific Officer & President of Global Biologics Researchno datageen gegevensgeen gegevens
Lina Fan
Senior VP & Head of Investor Relationsless than a yeargeen gegevensgeen gegevens
He Wang
Chief Compliance Officer2.2yrsgeen gegevensgeen gegevens
Li Xiong
VP & Head of Global Human Resourcesno datageen gegevensgeen gegevens
Angus Scott Turner
Senior VP and Head of Global BD & Alliance Managementno datageen gegevensgeen gegevens
Keqiang Shen
Chief Digital Officer4.8yrsgeen gegevensgeen gegevens

2.6yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2269 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Ge Li
Founder & Chairman10.8yrsgeen gegevensgeen gegevens
Zhisheng Chen
CEO & Executive Director10.8yrsCN¥96.91m0.35%
HK$ 208.6m
Weichang Zhou
Honorary President of Global Biologics Development8.5yrsCN¥32.89m0.013%
HK$ 8.0m
Jackson Tai
Independent Non-Executive Director1.5yrsCN¥710.00k0.00063%
HK$ 372.4k
James Larrick
Member of Scientific Advisory Board6.8yrsgeen gegevensgeen gegevens
David D. Ho
Member of Scientific Advisory Board6.8yrsgeen gegevensgeen gegevens
Wei-Shou Hu
Member of Scientific Advisory Board6.8yrsgeen gegevensgeen gegevens
Ram Sasisekharan
Member of Scientific Advisory Board6.8yrsgeen gegevensgeen gegevens
William Robert Keller
Independent Non-Executive Director7.5yrsCN¥906.00k0.00053%
HK$ 313.3k
Yanling Cao
Non-Executive Director8.5yrsgeen gegevensgeen gegevens
Yibing Wu
Non-Executive Director8.5yrsgeen gegevensgeen gegevens
Kenneth Walton Hitchner
Independent Non-Executive Director4.4yrsCN¥933.00k0.0050%
HK$ 2.9m

7.2yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2269 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.2 jaar).